about
Complement component C3 - The "Swiss Army Knife" of innate immunity and host defenseThe complement system as a potential therapeutic target in rheumatic disease.Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome-Biomarkers of the Disease and Biopharmaceuticals.TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement.From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.Protection of host cells by complement regulators.Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis in Vivo.Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling.Functional and structural characterization of four mouse monoclonal antibodies to complement C3 with potential therapeutic and diagnostic applications.The renaissance of complement therapeutics.Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.The Complement System Is Critical in Maintaining Retinal Integrity during Aging.Immunity against the obligate intracellular bacterial pathogen Rickettsia australis requires functional complement system.Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse GlaucomaChimeric Proteins Containing MAP-1 and Functional Domains of C4b-Binding Protein Reveal Strong Complement Inhibitory Capacities
P2860
Q38558926-BD1BBD3E-B2D3-475F-84BE-7157C01D2DF5Q38631542-78303F9E-EFF5-45BE-8CD4-01F35E1B3D9EQ38718092-1E79AFE0-9341-4D02-945F-2C3B0269E12CQ38766473-944447CA-010B-4D53-99F0-D04A9EEF7BE0Q38879877-C6A40592-338B-4FE4-9619-E5D39D303F5EQ38991019-B5B46DBB-F33A-4BA5-8FFB-4D57294FD986Q39246952-AA1BFDF5-5682-4B62-8239-9BC0EA607F90Q40398444-A0EE3254-78BE-4BEF-A5D2-7B873E12F1A6Q41010630-F505BDE2-F769-48C9-98CB-D5F753B9685DQ46433084-14A87869-0064-479F-A9A3-E433B9FAACBFQ47336749-C04C3696-E767-4D40-A789-9710823578E8Q47650832-5E724D12-0215-4055-8498-76AA0F2251EAQ51766201-A5C970B9-2911-4FBF-9304-9374F38BF84BQ52341129-94491686-DAF8-4574-8F1E-F83C68BCD1FCQ57039780-35DF21DC-C035-4CDE-AD4C-5E656F3F9747Q58698457-E583E6C2-F672-415E-BE58-F31A095DF478
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
New milestones ahead in complement-targeted therapy.
@ast
New milestones ahead in complement-targeted therapy.
@en
type
label
New milestones ahead in complement-targeted therapy.
@ast
New milestones ahead in complement-targeted therapy.
@en
prefLabel
New milestones ahead in complement-targeted therapy.
@ast
New milestones ahead in complement-targeted therapy.
@en
P2860
P1476
New milestones ahead in complement-targeted therapy.
@en
P2093
Daniel Ricklin
P2860
P304
P356
10.1016/J.SMIM.2016.06.001
P577
2016-06-16T00:00:00Z